$TherapeuticsMD (TXMD.US)$See some improvements in earnings but most importantly why I’ve got my attention here is the following statement from the company! ( said that it is exploring strategic alternatives for the company, which could include a business combination or sale of assets. ) Would love to see a big Pharma swoop in a buy! Thats why it has my attention! The company also released its Q3 financial report, posting a net loss from continuing operations of $0.13 per share...
TherapeuticsMD股票讨论
The company also released its Q3 financial report, posting a net loss from continuing operations of $0.13 per share...
利润表显示2022年的利润绝大部分来自1.11亿的停止经营利润,是不可持续的,持续经营利润仅107万,按目前4433万市值计算,市盈率达到41,可以再观察几个季度的情况再做判断。
• $美源伯根 (ABC.US)$ 德意志银行将其评级从持有升级为买入-目标价从167美元提高至178美元
• $Arch Resources (ARCH.US)$ 摩根大通将其持有评级上调为买入 - 目标价为225美元(由160美元上调)
• $必和必拓 (BHP.US)$ 摩根大通将其持有评级上调为买入 - 目标价为82美元(由72美元上调)
• $Peabody Energy (BTU.US)$ 摩根大通将其持有评级上调为买入 - 目标价为36美元(由25美元上调)
• $Warrior Met Coal (HCC.US)$ 摩根大通将其持有评级上调为买入 - 目标价为50美元(由36美元上调)
• $自由全球-A (LBTYA.US)$ :Berenbe...
暂无评论